Ignite Creation Date:
2024-10-26 @ 3:41 PM
Last Modification Date:
2024-10-26 @ 3:41 PM
Study NCT ID:
NCT06624085
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-10-01
Brief Title:
A Study Evaluating the Safety and Efficacy of Glofitamab Gemcitabine Oxaliplatin in US Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase Ib Study Evaluating the Safety Efficacy Pharmacokinetics and Pharmacodynamics of Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in US Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study is to evaluate glofitamab gemcitabine oxaliplatin in participants in the United States including under-represented racial and ethnic populations that have relapsed or refractory RR diffuse large B-cell lymphoma DLBCL
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None